Welcome to our dedicated page for Oric Pharmaceuticals news (Ticker: ORIC), a resource for investors and traders seeking the latest updates and insights on Oric Pharmaceuticals stock.
Oric Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, is dedicated to discovering and developing innovative therapies for the treatment of cancer. Headquartered in South San Francisco, California, Oric Pharmaceuticals was founded in 2014 and has since focused on addressing the challenging problem of cancer resistance to existing treatments.
The company's lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor. This receptor has been identified as a key player in the resistance mechanisms against various classes of cancer therapeutics, particularly across solid tumors. By targeting this receptor, ORIC-101 aims to enhance the effectiveness of existing cancer treatments.
Another significant asset in Oric's pipeline is ORIC-533, an orally bioavailable small molecule inhibitor of CD73. CD73 plays a role in resistance to both chemotherapy and immunotherapy, and ORIC-533 is being developed to counteract this resistance, offering a potential new avenue for treating patients who do not respond to current therapies.
In addition to ORIC-101 and ORIC-533, the company is also developing ORIC-944 and ORIC-114, each targeting different mechanisms of cancer resistance. ORIC-944 has shown promise in initial Phase 1b data, and the company has outlined several anticipated milestones for these programs in the near future.
Oric Pharmaceuticals demonstrates a robust commitment to advancing the field of precision oncology. The company leverages its expertise in hormone-dependent cancers, precision oncology, and key tumor dependencies to build a diverse pipeline of therapies. These efforts are supported by strategic partnerships and collaborations aimed at accelerating the development and commercialization of their treatment candidates.
Financially, Oric Pharmaceuticals has provided guidance and updates to keep stakeholders informed about their progress and strategic direction. For the latest news and developments, investors and interested parties are encouraged to stay tuned to the company's announcements.
Contact: Dominic Piscitelli, Chief Financial Officer
ORIC Pharmaceuticals (Nasdaq: ORIC), a clinical stage oncology company, has announced its participation in three major investor conferences in February 2025. The company will engage in fireside chats at the following events:
- Jones Research Precision Medicine Day on February 3 at 12:30 p.m. ET
- Guggenheim Securities SMID Cap Biotech Conference on February 5 at 1:30 p.m. ET
- Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11 at 12:00 p.m. ET
Live webcasts of these discussions will be accessible through the investor section of ORIC's website at www.oricpharma.com, with replays available for 90 days after each event.
ORIC Pharmaceuticals has reported encouraging early Phase 1b combination data for ORIC-944 in treating metastatic castration-resistant prostate cancer (mCRPC). The trial showed deep PSA decreases, with 3 of 6 patients achieving confirmed PSA50 responses and 2 achieving PSA90 responses. The treatment demonstrated favorable safety with primarily Grade 1 and 2 adverse events.
The company entered a clinical collaboration with Johnson & Johnson to evaluate ORIC-114 combined with amivantamab for first-line NSCLC treatment. ORIC expects seven data readouts across its clinical programs over the next 18 months, with potential registrational trials starting in 2H25 and early 2026.
Following a $125 million private placement financing, ORIC's cash position stood at $282.4 million as of September 30, 2024, expected to fund operations into late 2026.
ORIC Pharmaceuticals announced a clinical supply agreement with Janssen Research & Development to evaluate ORIC-114 in combination with amivantamab for the first-line treatment of non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. This Phase 1b trial is expected to begin in Q1 2025, with initial data anticipated by mid-2026.
The trial aims to assess the safety and tolerability of the combination therapy and determine the recommended Phase 2 dose (RP2D). ORIC will sponsor the trial, while Johnson & Johnson will supply amivantamab.
ORIC retains the development and commercial rights to ORIC-114 and may expand its use with other agents. The company highlighted that ORIC-114 has shown promising systemic and intracranial activity in heavily pre-treated patients with EGFR/HER2 mutated NSCLC. The trial will further explore its efficacy in the first-line setting, both as a monotherapy and in combination with amivantamab.
In 2024, ORIC completed the monotherapy dose escalation portion of the Phase 1b trial for ORIC-114 in patients with advanced solid tumors. Based on these data, two provisional RP2D levels (80 mg and 120 mg QD) were selected for further evaluation.
ORIC Pharmaceuticals (Nasdaq: ORIC), a clinical stage oncology company specializing in treatments for therapeutic resistance, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's CEO, Jacob M. Chacko, M.D., will deliver a company overview presentation on Tuesday, January 14, 2025, at 11:15 a.m. PT.
The presentation will be accessible via live webcast through the investor section of ORIC's website at www.oricpharma.com. Interested parties who cannot attend the live presentation will have access to a replay of the webcast, which will remain available for 90 days after the event.
ORIC Pharmaceuticals (Nasdaq: ORIC) has announced the granting of inducement awards to a new non-executive employee who joined in December 2024. The grants, approved on January 2, 2025, include 16,400 non-qualified stock options and 2,800 restricted stock units.
The stock options will vest 25% on the first anniversary of the grant date, with the remaining shares vesting monthly over the following three years. The restricted stock units will vest in three equal installments on each anniversary of the grant date. The exercise price for the stock options is set at the closing price of ORIC's common stock on January 2, 2025.
These inducement grants were made under the company's 2022 Inducement Equity Incentive Plan and were approved by ORIC's Compensation Committee in accordance with Nasdaq Rule 5635(c)(4).
ORIC Pharmaceuticals (Nasdaq: ORIC), a clinical stage oncology company, announced its participation in two upcoming investor conferences in December 2024. The company will join a fireside chat at the 7th Annual Evercore HEALTHCONx Conference on December 4 at 2:35 p.m. ET, and participate in the 'Novel Mechanisms in Oncology II' panel at Citi's 2024 Global Healthcare Conference on December 5 at 11:00 a.m. ET. Live webcasts will be accessible through ORIC's website, with replays available for 90 days after the events.
ORIC Pharmaceuticals reported Q3 2024 financial results and operational updates. The company presented preclinical data for ORIC-114, demonstrating potential best-in-class properties for treating EGFR exon 20 insertions. They announced clinical collaborations with Bayer and Johnson & Johnson for ORIC-944 trials in prostate cancer. Financial highlights include cash and investments of $282.4 million, expected to fund operations into late 2026. R&D expenses increased to $31.2 million in Q3 2024 from $22.4 million in Q3 2023, while G&A expenses rose to $7.1 million from $6.3 million in the same period.
ORIC Pharmaceuticals (Nasdaq: ORIC), a clinical stage oncology company, has announced its participation in two upcoming investor conferences in November 2024. The company will be featured in fireside chats at Guggenheim's Inaugural Healthcare Innovation Conference on November 11 at 10:30 a.m. ET and the Jefferies London Healthcare Conference on November 21 at 12:00 p.m. GMT. Live webcasts of both discussions will be accessible through ORIC's investor website section, with replays available for 90 days after the events.
ORIC Pharmaceuticals announced the granting of inducement equity awards to two new non-executive employees who joined in October 2024. The grants include 61,800 non-qualified stock options and 10,400 restricted stock units. The stock options will vest 25% after one year, with remaining shares vesting monthly over three years. The restricted stock units will vest one-third annually over three years. These grants were made under the company's 2022 Inducement Equity Incentive Plan and approved by the Compensation Committee in accordance with Nasdaq Rule 5635(c)(4).
ORIC Pharmaceuticals presented data highlighting ORIC-114's potential as a best-in-class EGFR/HER2 inhibitor for treating EGFR exon 20 insertions and other atypical mutations. The brain-penetrant, orally bioavailable treatment demonstrated superior potency across EGFR mutational classes compared to other inhibitors. Key findings showed tumor regressions in all tested EGFR mutant models, with 100% tumor regressions in complex atypical mutant EGFR models. The drug displayed superior kinome selectivity and complete molecular responses in ctDNA from patients. Updated data from Phase 1b expansion cohorts is expected in H1 2025.
FAQ
What is the current stock price of Oric Pharmaceuticals (ORIC)?
What is the market cap of Oric Pharmaceuticals (ORIC)?
What is Oric Pharmaceuticals, Inc.?
What is ORIC-101?
What is ORIC-533?
Where is Oric Pharmaceuticals headquartered?
When was Oric Pharmaceuticals founded?
What other products are in Oric Pharmaceuticals' pipeline?
What are the core areas of expertise for Oric Pharmaceuticals?
How can I contact Oric Pharmaceuticals for more information?
What is the company’s financial condition?
What recent achievements has Oric Pharmaceuticals made?
